Affiliation:
1. Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics
2. Department of Nuclear Medicine
3. Department of Biomedical Engineering and Physics, Medical University of Vienna
4. Institute of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Vienna, Austria
Abstract
ABSTRACT
The biodistribution and pharmacokinetics of the fluorine-18-labeled fluoroquinolone antibiotic [
18
F]ciprofloxacin in tissue were studied noninvasively in humans by means of positron emission tomography (PET). Special attention was paid to characterizing the distribution of [
18
F]ciprofloxacin to select target tissues. Healthy volunteers (
n
= 12) were orally pretreated for 5 days with therapeutic doses of unlabeled ciprofloxacin. On day 6, subjects received a tracer dose (mean injected amount, 700 ± 55 MBq, which contained about 0.6 mg of unlabeled ciprofloxacin) of [
18
F]ciprofloxacin as an intravenous bolus. Thereafter, PET imaging and venous blood sampling were initiated. Time-radioactivity curves were measured for liver, kidney, lung, heart, spleen, skeletal muscle, and brain tissues for up to 6 h after radiotracer administration. The first application of [
18
F]ciprofloxacin in humans has demonstrated the safety and utility of the newly developed radiotracer for pharmacokinetic PET imaging of the tissue ciprofloxacin distribution. Two different tissue compartments of radiotracer distribution could be identified. The first compartment including the kidney, heart, and spleen, from which the radiotracer was washed out relatively quickly (half-lives [
t
1/2
s], 68, 57, and 106 min, respectively). The second compartment comprised liver, muscle, and lung tissue, which displayed prolonged radiotracer retention (
t
1/2
, >130 min). The highest concentrations of radioactivity were measured in the liver and kidney, the main organs of excretion (standardized uptake values [SUVs], 4.9 ± 1.0 and 9.9 ± 4.4, respectively). The brain radioactivity concentrations were very low (<1 kBq · g
−1
) and could therefore not be quantified. Transformation of SUVs into absolute concentrations (in micrograms per milliliter) allowed us to relate the concentrations at the target site to the susceptibilities of bacterial pathogens. In this way, the frequent use of ciprofloxacin for the treatment of a variety of infections could be corroborated.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference28 articles.
1. Ball, P., and G. Tillotson. 1995. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety13:343-358.
2. Bergström, M., A. Grahnen, and B. Långström. 2003. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur. J. Clin. Pharmacol.59:357-366.
3. Berridge, M. S., D. L. Heald, and Z. Lee. 2003. Imaging studies of biodistribution and kinetics in drug development. Drug Dev. Res.59:208-226.
4. Birmingham, M. C., R. Guarino, A. Heller, J. H. Wilton, A. Shah, L. Hejmanowski, D. E. Nix, and J. J. Schentag. 1999. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. J. Antimicrob. Chemother.43(Suppl. A):43-48.
5. Fluoroquinolone Transport by Human Monocytes: Characterization and Comparison to Other Cells of Myeloid Lineage
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献